AA
CRDF icon

ALPS Advisors’s Cardiff Oncology CRDF Stock Holding History

ALPS Advisors’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-44,511
Closed -$110K – 1045
2022
Q1 		$110K Sell
44,511
-4,048
-8% -$14.3K ﹤0.01% 825
2021
Q4 		$292K Buy
48,559
+86
+0.2% +$513 ﹤0.01% 837
2021
Q3 		$323K Sell
48,473
-986
-2% -$6.19K ﹤0.01% 845
2021
Q2 		$329K Buy
+49,459
New +$419K ﹤0.01% 769

Other funds holding CRDF

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

ALPS Advisors's CRDF Position: Q2 2022 in Review

ALPS Advisors sold out of Cardiff Oncology (CRDF) in Q2 2022, closing a stake of 44,511 shares — an estimated $110K sold.

ALPS Advisors first reported a position in CRDF in Q2 2021 and held it in 4 quarters. The position peaked at $329K in Q2 2021. 67 funds tracked by Wall St. Rank hold CRDF as of Q2 2022.

  • ALPS Advisors reported no remaining Cardiff Oncology position as of Q2 2022 after selling out during the quarter.
  • ALPS Advisors sold 44,511 Cardiff Oncology shares in Q2 2022, an estimated $110K.
  • ALPS Advisors first reported a position in Cardiff Oncology in Q2 2021 and held it in 4 quarters.
  • ALPS Advisors's Cardiff Oncology position peaked at $329K in Q2 2021.
  • 67 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2022.

Based on ALPS Advisors's 13F filing for Q2 2022, filed 11 Aug 2022.